CUMBERLAND PHARMACEUTICALS overview

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update PR Newswire NASHVILLE, TENN., May 7, 2024 NASHVILLE, TENN . , May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., April 30, 2024 NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024 . A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the...

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS PR Newswire NASHVILLE, Tenn., April 2, 2024 Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting...

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire NASHVILLE, Tenn., March 5, 2024 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations....

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Feb. 27, 2024 NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024 . A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results. To...

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results PR Newswire NASHVILLE, Tenn., Nov. 7, 2023 NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date. Net loss for the third quarter was $1.0 million , while year-to-date net...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Oct. 31, 2023 NASHVILLE, Tenn. , Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023 . A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the...

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE PR Newswire NASHVILLE, Tenn., Oct. 10, 2023 NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy 1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ ® ( telavancin) injection in children 2 to 17 years of age. Vibativ is an intravenous...